Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03903549 · ClinicalTrials.gov registry record · Phase 1
Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers
A Phase 1 study, sponsored by Five Eleven Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03903549 is a Phase 1 study that has completed, run by Five Eleven Pharma. The registered enrollment target is 4 participants.
The verdict
NCT03903549, a Phase 1 study, has completed, sponsored by Five Eleven Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study investigates the initial safety profile of \[18F\]P17-059 in healthy volunteers including dosimetry determination, and compares regional brain uptake and kinetics of \[18F\]P17-059 in Parkinson's disease patients with regional brain uptake and kinetics of \[18F\]P17-059 in healthy volunteers.
Interventions
- DRUG [18F]P17-059
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03903549
The ClinicalTrials.gov registry entry for NCT03903549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Five Eleven Pharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]P17-059 is the first listed.
NCT03903549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03903549 about?
NCT03903549 is a clinical study titled "Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers". This study investigates the initial safety profile of \[18F\]P17-059 in healthy volunteers including dosimetry determination, and compares regional brain uptake and kinetics of \[18F\]P17-059 in Parkinson's disease patients with regional brain uptake and kinetics of \[18F\]P17-059 in healthy volunte...
What is the current status of trial NCT03903549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2022-07-15. Estimated completion is 2022-12-19.
What interventions are being tested in trial NCT03903549?
The interventions under investigation include: [18F]P17-059 (DRUG).
Who is sponsoring clinical trial NCT03903549?
This trial is sponsored by Five Eleven Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.